Browse this journal

Latest articles

‘Latest articles’ are articles accepted for publication in this journal but not yet published in a volume/issue. Articles are removed from the ‘Latest articles’ list when they are published in a volume/issue. Latest articles are citable using the author(s), year of online publication, article title, journal and article DOI.

Download Citation Download PDFs

Drug Evaluation

Review Article
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer
Zine-Eddine Khene & Yair Lotan
Published online: 13 Jun 2024
  • 0 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Review Article
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma
Nozomu Ogura, Shun Yamamoto & Ken Kato
Published online: 11 Jun 2024
  • 0 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Review Article
Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market
Isabel Río-Álvarez & Encarnación Cruz-Martos
Published online: 06 Jun 2024
  • 138 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Review Article
Non-TNF biologics and their biosimilars in rheumatoid arthritis
Tsz Ching Mok & Chi Chiu Mok
Published online: 22 May 2024
  • 61 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Research

Article
Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF)
Viktoria Moschetti, Susanne Buschke, Julia Bertulis, Kathrin Hohl & Dorothy McCabe
Published online: 19 May 2024
  • 195 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Original Research

Article
Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis
Yan Jiang, Yanan Huo, Yufeng Li, Xijian Kong, Bingwu Wang, Feng Liu, Xin Zheng, Yukun Li, Yunfa Yang, Yongsheng Xu, Qingyun Xue, Zhitian Hu, Yanfeng Xiao, Wen Ma, Yinhan Guo, Wei Yu & Weibo Xia
Published online: 16 May 2024
  • 80 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Research

Article
Biosimilars and access to biologic therapy in immune-mediated diseases
Rocío Vázquez-Sánchez, Marco Navarro-Dávila, Esther Ramírez Herráiz, Vicente Merino-Bohórquez, Joaquín Borrás-Blasco, Alberto Onteniente-González, Ana Iglesias-Lambarri & Eva Negro-Vega
Published online: 14 May 2024
  • 54 Views
  • 0 CrossRef citations
  • 0Altmetric

Editorial

Editorial
Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety
Anan S. Jarab, Shrouq R. Abu Heshmeh & Ahmad Z. Al Meslamani
Published online: 28 Feb 2024
  • 392 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Original Research

Article
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males
Anhye Kim, Jang Hee Hong, Wonsuk Shin, Hyounggyoon Yoo, Jin-Gyu Jung, Jean-Yves Reginster, SungHyun Kim, YunJu Bae, JeeHye Suh, Sera Kim, EunKyung Lee & Stuart Silverman
Published online: 22 Feb 2024
  • 589 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Perspective

Comment
Streamlining biosimilar development based on 20 years’ experience
Cecil Nick
Published online: 22 Feb 2024
  • 94 Views
  • 0 CrossRef citations
  • 0Altmetric

Special Report

Report
Short and long-term economic implications of biosimilars
Ahmad Z. Al Meslamani
Published online: 17 Jan 2024
  • 46 Views
  • 0 CrossRef citations
  • 0Altmetric

Letter to the Editor

Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease
Accepted author version posted online: 29 Apr 2022
  • 983 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days